ライフサイエンスコーパス: lymphoma cell line

1 ion in Jijoye cells (an EBV-positive Burkitt lymphoma cell line).

2 germinal center, memory) and from a Burkitt lymphoma cell line.

3 the highly IFN-sensitive Daudi human Burkitt lymphoma cell line.

4 well as in a latently gamma HV68-infected B-lymphoma cell line.

5 F-1alpha), as was binding to the 3201 feline lymphoma cell line.

6 n during malignant progression of a murine B-lymphoma cell line.

7 GH in a three-way translocation in a Burkitt lymphoma cell line.

8 irus induced from a body cavity-based B-cell lymphoma cell line.

9 egative control IgG2 in a CD20(+) human Raji lymphoma cell line.

10 5 to 10 minutes of contact with the RAMOS B-lymphoma cell line.

11 cell line SW-2 than for an antigen-negative lymphoma cell line.

12 ith western blotting in the HDLM-2 Hodgkin's lymphoma cell line.

13 ation screen in a CD20xCD3-sensitive human B lymphoma cell line.

14 nscription factor PU.1 and CD10 in several B-lymphoma cell lines.

15 ion is also observed in other CD9-positive B lymphoma cell lines.

16 CT-1 oncogene was originally identified from lymphoma cell lines.

17 raction was effective only in TP53wt Burkitt lymphoma cell lines.

18 5 correlate with resistance to vorinostat in lymphoma cell lines.

19 anidin-3-rutinoside, in several leukemia and lymphoma cell lines.

20 nt antiproliferative activity in non-Hodgkin lymphoma cell lines.

21 ptosis including Bcl-xl and Mcl-1 in several lymphoma cell lines.

22 ity in MM, mantle cell lymphoma, and Burkitt lymphoma cell lines.

23 riable antigenic expression on the different lymphoma cell lines.

24 g enzyme in primary natural killer cells and lymphoma cell lines.

25 erum starvation-induced apoptosis in human T lymphoma cell lines.

26 ssion is similar to that of primary effusion lymphoma cell lines.

27 he monoclonal antibody rituximab in vitro in lymphoma cell lines.

28 eceptor (BCR)-induced apoptosis in Burkitt's lymphoma cell lines.

29 rved in PC3 prostate cancer and Ramos B-cell lymphoma cell lines.

30 were enriched in PDX DLBCL models and human lymphoma cell lines.

31 ied in over half of the PMBLs and in Hodgkin lymphoma cell lines.

32 fectively induce apoptosis in several B-cell lymphoma cell lines.

33 -cell lymphoid cell lines and in non-Hodgkin lymphoma cell lines.

34 entified in a fusion transcript with bcl6 in lymphoma cell lines.

35 ibody resulted in apoptosis of human Burkitt lymphoma cell lines.

36 or lines and 0.025-0.22 micro M for leukemia/lymphoma cell lines.

37 entially identical to EBV-positive Burkitt's lymphoma cell lines.

38 ative, patient-derived anaplastic large cell lymphoma cell lines.

39 metalloproteinase (TIMP)-1 in various B cell lymphoma cell lines.

40 expressed in HHV-8-positive pleural effusion lymphoma cell lines.

41 on carcinoma cell lines but not in Burkitt's lymphoma cell lines.

42 TFO was also effective in other leukemia and lymphoma cell lines.

43 essential in TP53 wild-type (TP53wt) Burkitt lymphoma cell lines.

44 roliferation and induce apoptosis in Burkitt lymphoma cell lines.

45 or genes that increase the invasiveness of T lymphoma cell lines.

46 l death in aggressive histology human B-cell lymphoma cell lines.

47 when transfected into M12.4.5 and M12.4.1 B lymphoma cell lines.

48 ated to on-target cellular activity in model lymphoma cell lines.

49 vels were observed in HL and part of Burkitt lymphoma cell lines.

50 n the growth of tumor xenografts produced by lymphoma cell lines.

51 nes that are targeted by PRMT5 in aggressive lymphoma cell lines.

52 lymphomas, we overexpressed NR4A1 in several lymphoma cell lines.

53 hosphorylation in human diffuse large B-cell lymphoma cell lines.

54 n in wild type B cells and human mantle cell lymphoma cell lines.

55 translation in both non-Hodgkin and Hodgkin lymphoma cell lines.

56 tive activities against multiple myeloma and lymphoma cell lines.

57 platin and were up to 10-fold more active in lymphoma cell lines.

58 oma cell lines, primary MCL and other B cell lymphoma cell lines.

59 osphorylated TAK1, p38, and IkappaB-alpha in lymphoma cell lines.

60 rcoma-associated herpesvirus (KSHV)-infected lymphoma cell lines.

61 tle cell, anaplastic large cell, and Hodgkin lymphoma cell lines.

62 f NF-kappaB and p38 and induced apoptosis in lymphoma cell lines.

63 KSHV+ but not in Epstein-Barr virus (EBV)+ B-lymphoma cell lines.

64 nsive apoptosis in a variety of leukemia and lymphoma cell lines.

65 -induced apoptosis in the GC-sensitive pre-B lymphoma cell line, 697.

66 Stimulation of a B lymphoma cell line, A20, with intact anti-IgG antibody i

67 ivation with HHV-8-positive primary effusion lymphoma cell lines, activated the lacZ gene of T1H6 in

68 me-scale screens of the BCL-2-driven OCI-Ly1 lymphoma cell line after venetoclax exposure along with

69 , and HS-Sultan) and in diffuse large B cell lymphoma cell lines, although yin yang 1 protein (YY1) b

70 tivation of CD5-associated CK2 in a murine B-lymphoma cell line and a human T-leukemia cell line and

71 In a murine B lymphoma cell line and an I-E(d)-transfected fibroblast

72 ects of clofoctol on an EBV-positive Burkitt lymphoma cell line and confirmed the upregulation of all

73 l progression, we have used an E2A-deficient lymphoma cell line and DNA microarray analysis to identi

74 of exosomes derived from the DG75 Burkitt's lymphoma cell line and its sublines (LMP1 transfected an

75 stitutive CCL17 secretion of a human Hodgkin lymphoma cell line and prevent upregulation of costimula

76 spond to HA22, we isolated an HA22-resistant lymphoma cell line and showed that resistance was due to

77 de in vitro cytotoxicity data for additional lymphoma cell lines and also chronic lymphocytic leukemi

78 hore A23187 to induce apoptosis in Burkitt's lymphoma cell lines and by measuring classical markers o

79 ssed in three different types of non-Hodgkin lymphoma cell lines and clinical samples as well as in m

80 titutively activated in primary tumors and B lymphoma cell lines and curcumin down-modulates Syk acti

81 of the multivalent aptamer was confirmed on lymphoma cell lines and fresh clinical leukemia samples.

82 f NRP-1 in representative human leukemia and lymphoma cell lines and in a panel of bone marrow specim

83 Per2 levels were reduced in lymphoma cell lines and in acute myeloid leukemia (AML)

84 Further validation in human lymphoma cell lines and in primary B-cell tumors demonst

85 hibitors bortezomib or carfilzomib in select lymphoma cell lines and induced potent mitochondrial mem

86 loss-of-function screening in eight Burkitt lymphoma cell lines and integrated non-Burkitt lymphoma

87 onstrate that PRMT5 knockdown in non-Hodgkin lymphoma cell lines and mouse primary lymphoma cells lea

88 on of global cap-dependent synthesis in both lymphoma cell lines and normal donor lymphocytes.

89 uce reactive oxygen species (ROS) in human B-lymphoma cell lines and primary B-cell chronic lymphocyt

90 hat trigger nonapoptotic PCD in a range of B-lymphoma cell lines and primary B-cell malignancies.

91 ellular cytotoxicity against B-cell leukemia/lymphoma cell lines and primary chronic lymphocytic leuk

92 diated adhesion to fibronectin and VCAM-1 of lymphoma cell lines and primary CLL cells.

93 Engineered lymphoma cell lines and primary FL B cells carrying muta

94 a with hypocalcemic drugs sensitized human B lymphoma cell lines and primary human lymphoma cells to

95 FDC-mediated protection against apoptosis in lymphoma cell lines and primary lymphoma cells.

96 B-cell lymphoma cell lines and primary malignant B cells from p

97 ositive and -negative, anaplastic large cell lymphoma cell lines and primary patient tumours using th

98 we report the use of transformed non-Hodgkin lymphoma cell lines and primary samples to identify the

99 Using gene expression profiles of lymphoma cell lines and primary thymocytes treated with

100 tion of EZH2 A677 to a glycine (A677G) among lymphoma cell lines and primary tumor specimens.

101 usokine treatment led to direct apoptosis of lymphoma cell lines and primary tumors that otherwise we

102 In in vivo analyses of B-cell lymphoma cell lines and primary tumors, Syk inhibition i

103 and during cisplatin-induced apoptosis in B-lymphoma cell lines and spontaneous apoptosis of primary

104 phoma kinase-positive, anaplastic large cell lymphoma cell lines and that ectopically expressed JunB

105 ckdowns of IRF8 expression in a mouse B cell lymphoma cell line, and examined the effects of a null m

106 yc promoter by 46-fold in the Raji Burkitt's lymphoma cell line, and it was the most active enhancer

107 All compounds were further tested on six lymphoma cell lines, and eight showed potent growth inhi

108 of target genes in stable STAT6 transfected lymphoma cell lines, and elevated baseline expression le

109 BV-negative lines, in EBV-infected Burkitt's lymphoma cell lines, and in EBV-transformed lymphoblasto

110 ession of miR-34a was not toxic in several B lymphoma cell lines, and inhibition of miR-34a impaired

111 herpesvirus (KSHV)-infected primary effusion lymphoma cell lines, and its expression correlates close

112 hronic lymphocytic leukaemia and mantle cell lymphoma cell lines, and patients treated with idelalisi

113 cells mediate the apoptotic death of murine lymphoma cell lines, and whether dendritic cell effector

114 C-to-U RNA editing in natural killer cells, lymphoma cell lines, and, to a lesser extent, CD8-positi

115 n a subset of KSHV-infected primary effusion lymphoma cell lines as a consequence of altered processi

116 down-regulated in a variety of leukemia and lymphoma cell lines as well as in CD34+ cells from the b

117 toxicity in retargeting human PBMC against B-lymphoma cell lines as well as in mediating autologous B

118 nes, whereas it was expressed in non-Hodgkin lymphoma cell lines at levels comparable with normal B c

119 y shown to inhibit pro-liferation of several lymphoma cell lines at nanomolar concentrations in the a

120 hat anti-IgM-induced cell death in a human B lymphoma cell line, B104, is associated with early intra

121 cation in two KSHV-infected primary effusion lymphoma cell lines (BC-3 and BC-1) and in MTX-resistant

122 pression of siRNAs into the primary effusion lymphoma cell line BCBL-1 caused a substantial reduction

123 omes of a latently infected pleural effusion lymphoma cell line BCBL1.

124 f RNA extracted from frozen DLCL samples and lymphoma cell lines, BCL8 expression was detected in all

125 Mfn2-knockdown clones of a B-cell lymphoma cell line BJAB exhibited an increased rate of c

126 could be induced to kill the TRAIL-sensitive lymphoma cell line BJAB through a TRAIL-dependent mechan

127 mmortalized cell line IB4, and the Burkitt's lymphoma cell line BJAB.

128 the B cell receptor (BCR) on the immature B lymphoma cell line BKS-2 induces growth inhibition and a

129 WiDr) but promoted cell growth of Burkitt's lymphoma cell lines (BL30 and BL41) in a dose-dependent

130 In a Burkitt lymphoma cell line, both types of agents likewise stimul

131 as expressed in the poorly tumorigenic DAC B-lymphoma cell line but was significantly down-regulated

132 Infection of a primary effusion lymphoma cell line by vesicular stomatitis virus type G-

133 e myeloid leukemia and anaplastic large-cell lymphoma cell lines by inducing cell-cycle arrest and/or

134 NA expression in a panel of primary effusion lymphoma cell lines by real-time RT-PCR recapitulated so

135 vities against Y3-Ag1.2.3 and the rat T cell lymphoma cell line C58 (NT) D.1.G.OVAR.1.

136 r describe a unique feature of the Burkitt's lymphoma cell line CA46 that allowed us to clearly demon

137 rated, using a cellular assay in a Burkitt's lymphoma cell line (CA46-specific), that these effects w

138 In lymphoma cell lines carrying BCL6 translocations, small

139 JAB cell line or v-Rel in the chicken DT40 B-lymphoma cell line causes reduced expression of PU.1.

140 In certain lymphoma cell lines, cellular proliferation is stimulate

141 ng in three different types of non-Hodgkin's lymphoma cell lines, clinical samples, and mouse primary

142 We found that in mantle cell lymphoma cell lines, combined IKZF1/3 degradation with d

143 pesvirus (KSHV)-transformed primary effusion lymphoma cell lines contain ~70 to 150 copies of episoma

144 s isotype class switching in a murine B-cell lymphoma cell line; conversely, B cells from mice where

145 have performed in vitro studies with a human lymphoma cell line (Daudi) because its response to anti-

146 Here we describe two B-cell lymphoma cell lines (DB and RL) that differ in their sen

147 We show that in a lymphoma cell line derived from an ATM(-/-) mouse, two t

148 the status of NF-kappaB in two non-Hodgkin's lymphoma cell lines derived from mantle cell lymphoma (M

149 ng of a conditionally BCL6-deficient Burkitt lymphoma cell line, DG75-AB7, with a library of small mo

150 Expression of the Fas receptor on the B lymphoma cell lines did not correlate with their capacit

151 Using the chicken B lymphoma cell line DT40 as a model system, we investigat

152 oculation of both melanoma cell line B16 and lymphoma cell line EL-4.

153 When inoculated with a transplantable lymphoma cell line, EL4, the treated old mice showed sta

154 The murine EL4 lymphoma cell line exists in variants that are either se

155 Analysis of p27kip1 derived from Burkitt's lymphoma cell lines expressing high levels of p27kip1, B

156 In a range of Burkitt lymphoma cell lines, expression of DeltaCD79b was relati

157 examined by FACS analysis, only Raji (B cell lymphoma cell line), GM847 (fibroblast cell line), 293 (

158 lines, including two EBV-positive Burkitt's lymphoma cell lines, grew normally in the absence of miR

159 ation of endogenous CCR7 in the human T cell lymphoma cell line H9.

160 The t(14;18) B-cell lymphoma cell line had low GSH levels and sensitivity to

161 The diffuse large B cell lymphoma cell lines had a distinctive slow-migrating com

162 , on transfection of Raji cells, a Burkitt's lymphoma cell line harboring a transcriptionally inactiv

163 ivo, the stable lentiviral-transduced SuDHL4 lymphoma cell line harboring an inducible NR4A1 construc

164 Six lymphoma cell lines have 4- to 9-fold more binding sites

165 SHP-1 mRNA observed in various leukemia and lymphoma cell lines have been attributed to either the m

166 us, these results indicated that mantle cell lymphoma cell lines have distinct mechanisms sustaining

167 BV vIL-10 locus exclusively in the Hodgkin's lymphoma cell line, Hs 611.T, the expression of which we

168 rin on the viability of the cutaneous T-cell lymphoma cell lines HuT-78 and HH by using 3-(4,5-dimeth

169 ibitors on T-cell lymphoma, the human T-cell lymphoma cell line HUT78 was tested for sensitivity and

170 expression differences between two related T lymphoma cell lines, HuT78 and H9, were identified.

171 TAT6 phosphorylation in immune and Hodgkin's lymphoma cell lines, IL-13 binding, and cytotoxicity of

172 In lymphoma cell lines, IMGN529 induced G2/M cell cycle arr

173 Here we show that incubation of lymphoma cell lines in acidic conditions (pH 6.5) blocks

174 o analysis of KSHV-infected primary effusion lymphoma cell lines in the presence of 12-O-tetradecanoy

175 t the proliferation of myeloma and Burkitt's lymphoma cell lines in vitro without showing toxicity to

176 le of target-dependent killing of nonHodgkin lymphoma cell lines in vitro.

177 to inhibit the growth of several different B-lymphoma cell lines in vitro.

178 ved successful latent infection are cultured lymphoma cell lines.) In most latently infected lines, s

179 endent cytotoxicity against a broad panel of lymphoma cell lines including mantle cell lymphoma (MCL)

180 ncrease over HA22 were observed in various B lymphoma cell lines including WSU-CLL that contains only

181 xamination of a number of human leukemia and lymphoma cell lines, including Jurkat, Molt-4, and Sup-T

182 f TAK1 is abundantly expressed in a panel of lymphoma cell lines, including mantle cell, anaplastic l

183 d murine T cell acute lymphoblastic leukemia/lymphoma cell lines indicating that NOTCH1 signals are r

184 a library prepared from the BC-1 body cavity lymphoma cell line induced into KSHV lytic gene expressi

185 EBV-negative Burkitt lymphoma cell lines infected with either wild-type or tw

186 atinase B by the high grade B-cell Burkitt's lymphoma cell lines is consistent with previous findings

187 initiation within newly established Burkitt lymphoma cell lines is consistent with the transcription

188 domain of MDC-L supported adhesion of the T-lymphoma cell line, Jurkat, in a concentration- and diva

189 ts ability to support cell adhesion of the T-lymphoma cell line, Jurkat.

190 sed the protein tyrosine kinase Src in the B lymphoma cell line K46-17 mu m lambda.

191 cing of PTPN1 by RNA interference in Hodgkin lymphoma cell line KM-H2 resulted in hyperphosphorylatio

192 mples with data from RCOR1 knockdowns in the lymphoma cell lines KM-H2 and Raji yielded an RCOR1 loss

193 or cholesterol depleting therapy, we treated lymphoma cell lines known to be sensitive to the reducti

194 nfection of murine B cell blasts, a murine B lymphoma cell line (L10A), and immortalized human B cell

195 The human B-cell lymphoma cell line, L3055, formed solid tumors only when

196 erimental model using an FDC line, HK, and a lymphoma cell line, L3055, that resembles centroblasts.

197 r at the mRNA and protein levels relative to lymphoma cell lines lacking a 1q21 rearrangement.

198 ytic replication of EBV induced in a Burkitt lymphoma cell line latently infected with EBV.

199 rast to previous reports using CD20-positive lymphoma cell lines, lenalidomide down-regulated CD20 su

200 apoptosis has been investigated in two mouse lymphoma cell lines: line LY-as is radiation sensitive,

201 o an Epstein-Barr virus-negative Burkitt's B-lymphoma cell line, Louckes, and compared to virus induc

202 proliferation results were observed in two B lymphoma cell lines (LP-1 and U266) but interestingly no

203 the NF kappa B status for two murine B-cell lymphoma cell lines, LY-as (apoptosis-sensitive) and LY-

204 the expression of Bcl-2 in two murine B-cell lymphoma cell lines: LY-as, an apoptosis-proficient line

205 and Fas activation on three CD30+ cutaneous lymphoma cell lines (Mac-1, Mac-2 A, JK) derived from no

206 -497, miR-130a, miR24, and miR-155) in human lymphoma cell lines, mice engrafted with patient-derived

207 r transfectants generated in a murine B cell lymphoma cell line migrated in transwell chemotaxis assa

208 rmation of cytosolic Myddosome aggregates in lymphoma cell lines, mimicking the effect of dimerized T

209 We discovered a novel oncogene in a T-cell lymphoma cell line, multiple copies in T-cell lymphoma-1

210 Here we used 2 Myc-induced mouse B lymphoma cell lines, Myc5-M5 and Myc5-M12, which spontan

211 (P-gp) pump in a multidrug-resistant (MDR) B-lymphoma cell line, Namalwa/MDR1, and that this effect i

212 L3055, a B lymphoma cell line of germinal center (GC) origin, is de

213 y expressed the highest TIMP1 level among 29 lymphoma cell lines of various subtypes.

214 thylated, DAP-Kinase nonexpressing Burkitt's lymphoma cell line, only did so when treated with 5-aza-

215 erfering RNA treatment of the Jurkat human T lymphoma cell line or human peripheral blood T cells dis

216 The results were confirmed using a Burkitt's lymphoma cell line overexpressing transfected bcl-2.

217 bited growth of a MYC-dependent human B cell lymphoma cell line (P493) by blocking DNA replication, l

218 Burkitt lymphoma cell lines phenocopy the primary tumors with re

219 ith ibrutinib induced synergistic killing of lymphoma cell lines, primary human lymphoma specimens ex

220 ed cell survival and lymphoma progression in lymphoma cell lines, primary MCL and other B cell lympho

221 -transformed lymphoblasts, and many standard lymphoma cell lines produce high levels of granzyme B in

222 BC-1, a KSHV-DNA-positive, body cavity-based lymphoma cell line, produces infective herpesviral parti

223 In a cutaneous T-cell lymphoma cell line, promoter hypermethylation was shown

224 Reduction of SLIP-GC levels in the Burkitt lymphoma cell line Raji and in non-Hodgkin lymphoma cell

225 TIMP-2 promoter hypermethylation in the lymphoma cell line Raji and the leukemia cell line KG1a

226 Here we show that the Burkitt lymphoma cell line Raji represents an experimental syste

227 phorylation of Akt (serine 473) in Burkitt's lymphoma cell line Ramos and in gastric carcinoma cell l

228 gions for isotype switching, an IgM+ Burkitt lymphoma cell line (Ramos 2G6) was assayed for the up-re

229 rituximab against a variety of human B-cell lymphoma cell lines (Ramos, DHL-4, and FL-18) in vivo.

230 The human large B-cell lymphoma cell line RC-K8 has a rearranged REL locus that

231 ed at a chromosomal breakpoint in the B-cell lymphoma cell line, RC-K8; Drosophila ME31B, encoded by

232 t lymphoma cell line Raji and in non-Hodgkin lymphoma cell lines resulted in an increase in DNA break

233 on of CARD11 coiled-coil domain mutants into lymphoma cell lines resulted in constitutive NF-kappaB a

234 ic expression of TSC-22 in mouse leukemia or lymphoma cell lines resulted in delayed in vivo tumor fo

235 MP-1 expression in an EBV-negative Burkitt's lymphoma cell line results in a biphasic, in vivo tumor

236 s when challenged with the established mouse lymphoma cell line RMA-S-RAE-1beta, which overexpresses

237 is of the gammaHV68 latently infected B-cell lymphoma cell line S11E, but were also detected during l

238 glucocorticoid-induced apoptosis, the murine lymphoma cell lines S49.A2 and WEHI7.2.

239 Remarkably, a murine lymphoma cell line, several human B cell cancer lines, a

240 cells, on various lymphoblastoid and Burkitt lymphoma cell lines, some of them being inducible or not

241 toxin uptake and toxin-mediated killing of B lymphoma cell lines, suggesting an alternative approach

242 udies of the t(2;5) translocation-containing lymphoma cell line SUP-M2 showed NPM-ALK to be localized

243 xpression of this tRNA-derived microRNA in a lymphoma cell line suppresses proliferation and modulate

244 SUPT-11 T-cell leukemia and P3HR-1 Burkitt's lymphoma cell lines, TCL1 interacts with endogenous Akt1

245 s significantly reduced off-rates in 3 human lymphoma cell lines tested, as well as increased complem

246 o PEL in vitro and in vivo, but not to other lymphoma cell lines tested.

247 In RL and CA46, two B-cell lymphoma cell lines, TGF-beta1 treatment caused down-reg

248 itors are far more cytotoxic for myeloma and lymphoma cell lines than for hepatocarcinoma or non-acti

249 identified as being overexpressed in a mouse lymphoma cell line that had gained resistance to cell de

250 In BC-1, a primary effusion lymphoma cell line that is dually infected with EBV and

251 A T-cell lymphoma cell line that is SHP-1 deficient (Karpas 299)

252 In pleural effusion lymphoma cell lines that express variable levels of KSHV

253 ct processes, we isolated stably transfected lymphoma cell lines that expressed either murine wild-ty

254 nt a mechanism of resistance to apoptosis in lymphoma cell lines that might be relevant for the devel

255 ngle agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy

256 4 hours varied widely in the seven different lymphoma cell lines that were tested, ranging from 35 to

257 We further show, in the BL2 Burkitt's lymphoma cell line, that KLHL6 interacts with Cullin3, b

258 As in all primary effusion lymphoma cell lines, there is a low level of spontaneous

259 sublines were isolated by exposing a Burkitt lymphoma cell line to increasing concentrations of vincr

260 Exposure of splenic marginal zone lymphoma cell lines to a demethylating agent caused part

261 Bcl-2 and susceptibility of human Burkitt's lymphoma cell lines to H2O2-induced killing.

262 2 and BCR ligation triggered several Burkitt lymphoma cell lines to undergo apoptosis, and the 2 stim

263 rther, transient Flag-LMP1 expression in a B-lymphoma cell line transduces signals that upregulate TR

264 osensitivity assays, using the L5178 mouse T lymphoma cell line transfected with the human MDR1 gene.

265 Cultured lymphoma cell lines treated with 4.35 showed dephosphory

266 In Jurkat cells, a human T-cell lymphoma cell line, tumor necrosis factor-alpha (TNF-alp

267 The assay was evaluated with the histiocytic lymphoma cell line U937 and the topoisomerase inhibitors

268 O was used to screen the proteome of a human lymphoma cell line (U937) sensitive to CDDO-induced apop

269 d with full-length BAFF, or by a histiocytic lymphoma cell line (U937) that expresses BAFF endogenous

270 er pretargeted RIT varied depending upon the lymphoma cell line used, with 1F5 Ab-SA and Lym-1 Ab-SA

271 rom initially sensitive OCI-Ly1 and SU-DHL-4 lymphoma cell lines via long-term exposure.

272 n siRNA-mediated IRF8 knockdown mouse B cell lymphoma cell line, we showed that IRF8 represses Bcor a

273 ulture system of primary human T cells and B lymphoma cell lines, we demonstrate a range of sensitivi

274 liferation of a number of human leukemia and lymphoma cell lines, we examined the role of p38 mitogen

275 In the current study with four mantle cell lymphoma cell lines, we report a new major metabolic pat

276 leads to apoptosis of EBV-infected LCLs and lymphoma cell lines, we sought to determine whether LMP1

277 phate receptor (IP(3)R) levels in two murine lymphoma cell lines, WEHI7.2 and S49.A2.

278 Subclones of the NK-92 human natural killer lymphoma cell line were derived by treatment with 5-aza-

279 Growth and survival of multiple lymphoma cell lines were studied with either drug alone

280 ell) or epithelial origin and five Burkitt's lymphoma cell lines were studied.

281 Ramos cells, a B-cell lymphoma cell line, were used as target cells for the ge

282 DNA from the KS-1 cells (a primary effusion lymphoma cell line which is estimated to have 16 copies

283 G methylation of the EBV genome in Burkitt's lymphoma cell lines which maintain type I latency, and l

284 in expression is also increased in Burkitt's lymphoma cell lines, which are known to have increased c

285 e arrest in Burkitt and diffuse large B-cell lymphoma cell lines, which are model cells for studying

286 A panel of murine B lymphoma cell lines, which express different levels of F

287 eath (apoptosis) response in three different lymphoma cell lines, which plays a key role in the devel

288 , of the ICOS gene, whereas cutaneous T-cell lymphoma cell lines, which strongly express ICOS, show n

289 oligonucleotides had no effect on two B-cell lymphoma cell lines, which were not infected with KSHV.

290 E710.2.3 is a murine thymic lymphoma cell line with an immature phenotype (CD4-CD8-)

291 An Epstein-Barr virus (EBV)-negative Burkitt lymphoma cell line with ectopic TIMP-1 expression (TIMP-

292 In Burkitt lymphoma cell lines with chromosome 1q21 abnormalities,

293 In the current study, lymphoma cell lines with constitutively active NF-kappaB

294 reports the effects of bortezomib in B-cell lymphoma cell lines with differing sensitivity to bortez

295 We labeled 2 murine lymphoma cell lines with dual function reporter genes an

296 h of human prostate cancer, lung cancer, and lymphoma cell lines with EC(50) values of 0.13, 0.56, an

297 th of human lung cancer and BP3 human B-cell lymphoma cell lines with EC(50) values of 0.33 and 0.66

298 l growth inhibitory activity in leukemia and lymphoma cell lines with high levels of phosphorylated S

299 ependent reduction in cell viability in five lymphoma cell lines, with EC(50) values ranging from 6 n

300 ntitumor efficacy against a syngeneic B cell lymphoma cell line within a background of normal CD19(+)